NCT02332850: Phase Ib Study of SAR650984 With Carfilzomib for Treatment of Relapsed Multiple Myeloma
- Recruiting
- Dec 23, 2015
- 1 min read
Updated: Jun 13, 2022
Multiple Myeloma Research Consortium
NCT02332850: Phase Ib Study of SAR650984 With Carfilzomib for Treatment of Relapsed Multiple Myeloma
Isa-Kd
This phase Ib trial studies the side effects and best dose of isatuximab when given together with carfilzomib with or without dexamethasone and lenalidomide in treating patients with multiple myeloma that has returned after a period of improvement (relapsed) or has not respond to previous treatment (refractory). Immunotherapy with monoclonal antibodies, such as isatuximab, may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread.
Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as dexamethasone and lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving isatuximab and carfilzomib with or without dexamethasone and lenalidomide may be a better treatment for patients with multiple myeloma.
Sponsor
Thomas Martin, MD
Collaborators
Amgen
Sanofi
ClinicalTrials.gov Identifier: NCT02332850
Official Title: A Multi-ARM Phase Ib Study of SAR650984 (Isatuximab, an Anti-CD38 mAb) in Combination With Standard Carfilzomib, and High-dose Weekly Carfilzomib and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma
First Posted : January 7, 2015
Click here for details on ClinicalTrials.gov
* Isatuximab (SARCLISA)
* Carfilzomib (Kyprolis)
* Dexamethasone (Decadron)
- California: University of California San Francisco
- New York: Tisch Cancer Institute Mount Sinai Hospital New York
- New Jersey: Hackensack University Medical Center
Locations
United States, California
United States, New Jersey
United States, New York
United States, Tennessee